Alpha Tau Medical Ltd. (Nasdaq: DRTS) sits at the center of that shift. The company is developing Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), a localized treatment designed to harness the destructive power of alpha particles inside solid tumors. Alpha particles have long been known for their ability to cause irreparable double-strand DNA breaks, but their extremely short range historically made them impractical for treating solid cancers. Alpha Tau’s approach addresses that limitation by allowing alpha-emitting atoms to diffuse throughout tumor tissue after intratumoral placement, extending therapeutic reach while maintaining localized exposure.
From Brain Tumors to Prostate Cancer: Expanding the Clinical Footprint
That precision is now being tested in some of oncology’s most challenging indications. In December, Alpha Tau announced that the first patient had been treated in a pilot study for recurrent glioblastoma multiforme (GBM), marking the first known use of Alpha DaRT in brain cancer. The procedure was performed at The Ohio State University using a delivery system designed to integrate with standard neurosurgical navigation platforms. According to the company, more than 95% of the tumor volume was covered during treatment, demonstrating technical feasibility in one of medicine’s most sensitive anatomical regions.
The GBM study joins a growing list of indications under active investigation. Alpha Tau recently received FDA approval to initiate a pilot study in locally recurrent prostate cancer, its fifth active Investigational Device Exemption in the U.S. The company is also advancing clinical programs in pancreatic cancer, recurrent head and neck cancer, and cutaneous squamous cell carcinoma, reflecting a strategy focused on tumors with high unmet need and limited local treatment options.
How the Giants Are Playing the Same Game
While Alpha Tau represents a smaller, highly specialized innovator, its work aligns with a broader push by much larger companies to redefine what precision oncology can achieve.
One of the most established players in radiation oncology is Siemens Healthineers AG (OTC: SIEGY), through its Varian business, which it acquired in 2020 for $16.4 billion. Varian has spent decades developing external-beam radiotherapy systems, including intensity-modulated radiation therapy and image-guided platforms designed to increase targeting accuracy. According to Siemens Healthineers, Varian’s technologies are used in thousands of treatment centers worldwide and continue to evolve toward adaptive and AI-supported radiation planning.
On the pharmaceutical side, Roche Holding AG (OTCQX: RHHBY) has taken a different but complementary approach by advancing targeted cancer therapies designed to work alongside localized treatments. Through its Genentech division, acquired in 2009 for $47 billion, Roche has developed multiple oncology platforms, including antibody-drug conjugates and precision diagnostics intended to match therapies to specific tumor biology. The oncology community got the latest piece of great cancer drug news on Monday when Roche said the FDA has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab), as a subcutaneous formulation, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Another global leader, AstraZeneca PLC (NASDAQ: AZN) has focused heavily on precision oncology through targeted therapies and radiopharmaceutical collaborations. The company has disclosed ongoing work in cancer treatments that aim to deliver potent therapeutic payloads directly to tumor cells while minimizing systemic toxicity. Much like Roche, AstraZeneca had important news on Monday, disclosing that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation in the U.S. for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Inside-Out Radiation: A Different Delivery Mechanism
What differentiates Alpha Tau within this landscape is its method of delivering radiation from inside the tumor outward, rather than directing beams or systemic agents inward. Alpha DaRT uses radium-224 sources inserted directly into the tumor, where short-lived daughter atoms diffuse locally and emit high-energy alpha radiation over a confined range. According to the company, this design allows for intense tumor cell destruction while limiting exposure beyond the tumor margins.
Early clinical results have drawn attention. In a first-in-human study involving certain skin and head and neck cancers, Alpha Tau reported a 100% overall response rate, with complete responses in more than 78% of patients, including tumors previously resistant to radiation. Treatments were delivered in a single outpatient session, with a mild side-effect profile reported by the company.
The broader implication is not that Alpha Tau replaces existing radiation or systemic therapies, but that it potentially expands the toolkit available to oncologists. For patients with recurrent tumors, radio-resistant disease, or cancers located near critical structures, localized alpha-based therapy may offer an alternative where conventional approaches fall short.
For investors interested in learning more about Alpha Tau, particularly those in the New York area, the company is scheduled to present at the upcoming DealFlow Discovery Conference in Atlantic City on January 28–29, 2026.
As major healthcare companies continue refining large-scale platforms and combination therapies, Alpha Tau is advancing a highly focused solution aimed at some of oncology’s most difficult problems. If its ongoing trials continue to demonstrate safety and feasibility across multiple indications, Alpha DaRT could represent a meaningful addition to the evolving precision-cancer landscape, one defined not by louder beams or broader exposure, but by controlled power delivered exactly where it is needed.
Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
View more of this article on AllPennyStocks.com.
About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: ads@allpennystocks.com
Phone: (800) 558-4560 Ext: 101
]]>